MOS

Analyst Note: The Mosaic Company (MOS)

Date: 2026-06-13 Current Price: $22.90

1. Structural Readiness

• State: Context-Only
• Conservative Entry: —
• Breakout Level: —
• Extension: —
• ATR Current: 4.7% (High)
• Pivot Strength: —

2. Thesis Layer

This is a TACTICAL, setup-led name with NO named secular thesis at this date. Per the StoryStocks framework, we do not invent a macro thesis where none is explicitly named. The conviction for MOS at this juncture must be derived strictly from the quality of the business fundamentals and the readiness of the technical setup (which is currently absent). The name is being judged on its operational execution and cost structure rather than a specific secular growth narrative or macro tailwind.

3. The Business

The Mosaic Company is the world's leading producer and marketer of concentrated phosphate and potash crop nutrients, operating globally with a focus on the top four nutrient-consuming countries: China, India, the U.S., and Brazil. The business is structured into three distinct segments: Phosphates, Potash, and Mosaic Fertilizantes.

Operational Highlights (as of Q1 2026):

• Phosphate Operations: The company reported that Bartow, Riverview, and Faustina facilities operated at or above 80% capacity in Q1 2026. The New Wales facility, Mosaic's largest, completed an extensive planned turnaround in March 2026, positioning it for higher operating rates in the future. However, management noted that due to elevated raw material costs, they are partially reducing production rates at Bartow and Louisiana and scaling back fertilizer production in Brazil.
• Sales Volume: In the first quarter of 2026, Mosaic sold 1.9 million tonnes of phosphate, driven by deferred demand from the end of 2025 returning.
• Potash Operations: The Potash segment's net sales increased to $667.4 million in Q1 2026, up from $570.2 million in the prior year period, primarily due to higher average selling prices. Operating rates for potash production were 77%, comparable to the 78% rate in the prior year.
• Strategic Divestitures: In March 2026, Mosaic committed to disposing of the Araxá mining and chemical complex in Brazil, classifying it as held for sale, which resulted in a $232.6 million impairment loss. Additionally, an agreement was entered in December 2025 to sell the Carlsbad, New Mexico potash mine for approximately $30 million, with the transaction expected to close in the first half of 2026.
• Financial Position: The company completed a $900 million public bond offering in November 2025, consisting of senior notes due 2029 and 2030.

Cost Environment: Management expects realized sulfur costs of roughly $540 per tonne and ammonia costs of roughly $610 per tonne for the second quarter of 2026. These elevated input costs, driven by limited availability and geopolitical volatility (specifically in the Middle East and Russia/Ukraine), have pressured margins despite higher selling prices.

4. Archetype and Conviction

• Archetype: Quality Compounder (with cyclical recovery characteristics).
• Rationale: The company demonstrates the characteristics of a Quality Compounder through its market leadership (72% of North American phosphate production), integrated supply chain, and ability to manage complex global logistics. The recent strategic moves—reducing CapEx guidance by $250 million to $1.25 billion for 2026 and divesting non-core assets like Araxá and Carlsbad—signal a management team focused on capital discipline and optimizing the balance sheet rather than aggressive expansion.
• Valuation Context: The financial spine indicates a forward consensus EPS of $0.81 for FY1 and $1.81 for FY2. This suggests a significant earnings recovery trajectory is priced in or expected by the market, aligning with the "Quality Compounder" archetype where earnings growth drives value.
• Conviction Stack:
• Thesis Strength: Low (No named secular thesis).
• Evidence Quality: High (Strong operational data from Q1 2026 earnings and filings).
• Structural Quality: Low (No technical setup defined).
• Setup Readiness: None (Context-only state).
• Rerating Potential: Moderate, contingent on the resolution of input cost pressures and the successful execution of the asset divestitures.

The high ATR (4.7%) indicates significant volatility, which is typical for cyclical commodity names but requires careful position sizing if a setup were to form. Currently, the lack of a defined technical structure prevents a high-conviction structural trade.

5. Invalidations, Strengtheners, and Gaps

• Invalidation Factors:
• Further escalation of geopolitical conflicts restricting sulfur/ammonia exports beyond current expectations, leading to deeper margin compression.
• Failure to close the Carlsbad or Araxá divestitures as planned, tying up capital.
• Strengtheners:
• Successful completion of the New Wales turnaround leading to sustained >80% phosphate operating rates.
• Realization of the $1.25 billion CapEx reduction without compromising long-term growth projects.
• Doubling of Mosaic Biosciences revenues as guided for 2026.
• Gaps in Evidence:
• Forward Guidance Nuance: While CapEx is lowered, specific guidance on Q2 2026 volume targets or margin recovery timelines beyond the cost estimates is not explicitly detailed in the provided snippets.
• Divestiture Timing: The exact closing date for the Carlsbad sale is "expected" in H1 2026, but the precise timing and final proceeds are subject to market conditions.

PRIVATE ANALYST CALL

Judgment: Hold Confidence: medium Key evidence: Q1 2026 phosphate sales volume of 1.9 million tonnes driven by deferred demand; strategic CapEx reduction of $250 million to $1.25 billion for 2026; successful completion of New Wales turnaround positioning for higher future rates. Key risks: Elevated sulfur and ammonia costs ($540/$610 per tonne) pressuring margins despite higher selling prices; geopolitical volatility restricting raw material exports; high current volatility (4.7% ATR) without a defined technical entry. Expected path: Management expects to see margin stabilization as the New Wales turnaround yields higher rates and asset divestitures (Araxá, Carlsbad) provide cash flow, while the company maintains disciplined capital allocation. Expected horizon: 6-12 months for the strategic divestitures and cost structure adjustments to fully reflect in earnings.